Valeant Pharmaceuticals (VRX) PT Lowered to $19 at Deutsche Bank
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Valeant Pharma (VRX) Falls Another 4%
March 7, 2017 9:43 AM ESTValeant Pharma (NYSE: VRX) is down another 4.1% early to $11.90, a fresh multi-year low. Deutsche Bank cut its price target to $19 earlier and Wells Fargo David Maris reiterated that new debt will lower EPS.
... MoreValeant (VRX) Refinancing will Lower Consensus EPS and Likely Means $8B in Asset Sales 'Off the Table' - Wells Fargo's Maris
March 6, 2017 10:32 AM ESTWells Fargo analyst David Maris weighed in on Valeant Pharmaceuticals (NYSE: VRX) after the company announced it intends to refinance some of its debt.
Maris said while they are "still working through how much this will negatively impact consensus EPS, but... More
Mizuho Securities Reiterates Underperform Rating and $9 PT on Valeant Pharmaceuticals (VRX); 'Debt Refinance May Decrease Earnings' 'Cloudy Outlook'
March 6, 2017 9:18 AM ESTMizuho Securities analyst Irina Koffler reiterates Underperform rating and $9 price target on Valeant Pharmaceuticals (NYSE: VRX), as the company announced a debt refinancing, that may increase interest expenses and decrease earnings to shareholders.
Koffler comments, "The company is using its recently... More
